The ASCO Post™ is published by Harborside Press, LLC under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in The ASCO Post™ do not necessarily reflect those of Harborside Press, LLC, HSP News Service, LLC, or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Harborside Press, HSP News Service, LLC, and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions. |
|
|
In the German phase II PAPGEMO trial reported in JAMA Oncology, Hans-Joachim Schmoll, MD, PhD, and colleagues found that the combination of pazopanib and gemcitabine improved 12-week progression-free survival vs pazopanib alone in patients with anthracycline- or ifosfamide-refractory soft-tissue sarcoma.
Recent research has shed new light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. A study published by Lei Wei, PhD, and colleagues in Science Advances detailed a method to measure the abundance of cancer-related early changes to skin tissue long before the damage becomes visible to the eye.
During the ASCO20 Virtual Education Program, Sarah A. McLaughlin, MD, FACS, presented a review of study data on the surgical and radiation oncology considerations to reduce the risk of lymphedema. The ASCO Post recently talked with Dr. McLaughlin about the perils of this common condition, how clinicians can reduce patients' lymphedema risk, and the role palliative medicine plays in reducing the symptom burden for patients.
Women who undergo mastectomy with reconstructive surgery as part of breast cancer treatment may face the risk of persistent use of opioids and sedative-hypnotic drugs, according to data presented by Jacob Cogan, MD, and colleagues.
Among patients with breast cancer treated with radiotherapy, symptoms were commonly underrecognized in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having significantly increased odds of symptom underrecognition. These findings were reported by Reshma Jagsi, MD, DPhil, and colleagues.
